• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
【24h】

Ocrelizumab: a B-cell depleting therapy for multiple sclerosis

机译：ocrelizumab：多发性硬化症的B细胞耗尽治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction. Multiple sclerosis (MS) is the most common neurological disease responsible for early disability in the young working population. In the last two decades, based on retrospective/prospective data, the use of disease-modifying therapies has been shown to slow the rate of disability progression and prolonged the time to conversion into secondary-progressive MS (SPMS). However, despite the availability of several approved therapies, disability progression cannot be halted significantly in all MS patients.Areas covered: This article reviews the immunopathology of the B-cells, and their role in pathogenesis of MS and their attractiveness as a potential therapeutic target in MS. The review focuses on the recently published ocrelizumab phase III trials in terms of its efficacy, safety, and tolerability as well as its future considerations.Expert opinion: B lymphocyte cell depletion therapy offers a compelling and promising new option for MS patients. Nonetheless, there is a need for heightened vigilance and awareness in detecting potential long-term consequences that currently remain unknown.
机译：介绍。多发性硬化症（MS）是最常见的神经系统疾病，其年轻工作人群中的早期残疾。在过去的二十年中，基于回顾性/前瞻性数据，已经证明了使用疾病改性疗法来减缓残疾进展的速度，并延长转换成二次逐步MS（SPM）的时间。但是，尽管有几种批准的疗法可用，但在所有MS患者中，残疾进展都不能明显停止。涉及：本文审查了B细胞的免疫病理学，以及它们在MS发病机制中的作用及其作为潜在治疗目标的吸引力在ms。该审查在其疗效，安全性和可耐受性以及其未来的考虑方面重点介绍最近发表的ocrelizumab阶段III试验。患者意见：B淋巴细胞细胞耗尽治疗为MS患者提供了令人瞩目和有希望的新选择。尽管如此，在检测目前仍然未知的潜在长期后果的情况下，需要提高警惕性和意识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号